These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35139160)

  • 21. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
    Aoun M; Salloum R; Dfouni A; Sleilaty G; Chelala D
    Clin Nephrol; 2020 Aug; 94(2):61-69. PubMed ID: 32589132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
    Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W
    Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Febuxostat-Associated Myopathy in Patients with CKD.
    Liu CT; Chen CY; Hsu CY; Huang PH; Lin FY; Chen JW; Lin SJ
    Clin J Am Soc Nephrol; 2017 May; 12(5):744-750. PubMed ID: 28302902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving cardiovascular and renal outcomes in gout: what should we target?
    Richette P; Perez-Ruiz F; Doherty M; Jansen TL; Nuki G; Pascual E; Punzi L; So AK; Bardin T
    Nat Rev Rheumatol; 2014 Nov; 10(11):654-61. PubMed ID: 25136785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
    Kim SC; Schmidt BM; Franklin JM; Liu J; Solomon DH; Schneeweiss S
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2008-14. PubMed ID: 23861232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
    Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
    Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gout: state of the art after a decade of developments.
    Pascart T; Lioté F
    Rheumatology (Oxford); 2019 Jan; 58(1):27-44. PubMed ID: 29547895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
    Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
    Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
    Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
    Khimion LV; Burianov OA; Nayshtetik IM; Rotova SO; Smiyan SI; Danyliuk SV; Trofanchuk VV
    Wiad Lek; 2022; 75(5 pt 1):1059-1063. PubMed ID: 35758478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L
    Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
    Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
    Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.